These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20431732)

  • 21. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
    Deltenre P; Louvet A; Lemoine M; Mourad A; Fartoux L; Moreno C; Henrion J; Mathurin P; Serfaty L
    J Hepatol; 2011 Dec; 55(6):1187-94. PubMed ID: 21703195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
    Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
    Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Pol S; Halfon P
    Antivir Ther; 2009; 14(6):839-45. PubMed ID: 19812446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
    Husa P; Slesinger P; Stroblová H; Svobodník A
    Vnitr Lek; 2006 Feb; 52(2):153-9. PubMed ID: 16623278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
    Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
    Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
    J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.
    Delgado-Borrego A; Jordan SH; Negre B; Healey D; Lin W; Kamegaya Y; Christofi M; Ludwig DA; Lok AS; Chung RT;
    Clin Gastroenterol Hepatol; 2010 May; 8(5):458-62. PubMed ID: 20156586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
    Durante-Mangoni E; Zampino R; Portella G; Adinolfi LE; Utili R; Ruggiero G
    Clin Infect Dis; 2009 Aug; 49(4):498-506. PubMed ID: 19591593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.